Aclarion Inc (ACON) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Aclarion Inc $3.41, price $2.34, upside +45.7%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
54‑month range $2.02 – $393,638 · fair‑value band $2.25 – $4.26 · the $2.34 price screens below the $3.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Aclarion in your weekly email
Every Wednesday you see whether Aclarion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
Show more
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Stock analysis
Aclarion Inc (ACON) currently trades at $2.34, while our model-based Fair Value estimate is $3.41, implying the stock looks roughly 31.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.25 (bear) to $4.26 (bull), the price of $2.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Aclarion Inc reported revenue of $75.7K in FY2025 versus $60.3K in FY2021, a compound +5.9%/yr. Reported net income was −$7.2M in FY2025.
Key figures
Market cap $6.9M · P/S ratio 81.9 · EPS (TTM) $−6.96 · Return on equity −59.0% · Return on assets (EBIT) −171% · Operating margin −11,503% · Revenue (TTM) $83.8K · Revenue growth (YoY) +30.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 46%, ACON screens cheaper than that median.
Fair Value models
Bear $2.25Fair Value $3.41Bull $4.26
Price $2.34 · Upside +45.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+65.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−9,203.0% (2020) → −9,312.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside+45.7% · Top 25%
Profitability
Return on assets−37.0% · Bottom 25%
Growth and dividend
Revenue growth30.5% · Top 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Aclarion Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACON
Frequently asked questions
Is Aclarion Inc (ACON) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $3.41 versus a price of $2.34, about +46% upside (undervalued).
What is the fair value of ACON?
Our model-based fair value for Aclarion Inc is $3.41 (as of Oct 3, 2026), built from audited fundamentals. The current price: $2.34.
What is the quality score of ACON?
Aclarion Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aclarion Inc (ACON)?
Our model-based price target is the fair value of $3.41 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $2.25, optimistic scenario $4.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Aclarion Inc stock forecast for 2026?
Our models put fair value at $3.41, about +46% upside versus a price of $2.34 (undervalued). Cautious scenario $2.25, optimistic scenario $4.26. The calculation is refreshed regularly with new filings.
What is the revenue of Aclarion Inc (ACON)?
Aclarion Inc reported trailing-twelve-month revenue of about $83.8K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Aclarion Inc (ACON)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aclarion Inc it is $3.41 per share (as of Oct 3, 2026), against a price of $2.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aclarion Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ACON trades below its calculated fair value: price $2.34, fair value $3.41, a gap of about +46% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACON?
No. The price is what the market pays today ($2.34); the fair value is what the company's own numbers justify ($3.41). For Aclarion Inc the two are $1.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aclarion Inc worth?
The market values Aclarion Inc at about $6.9M (market capitalisation, as of Oct 3, 2026). Per share that is $2.34; our models calculate a fair value of $3.41 per share.
What do the bullish and bearish scenarios say about ACON?
Our models span a range for Aclarion Inc: cautious scenario $2.25, base $3.41, optimistic $4.26 per share (as of Oct 3, 2026, price $2.34). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aclarion Inc (ACON)?
Balance-sheet figures for Aclarion Inc (as of Oct 3, 2026): return on equity −59.0%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is ACON from its 52-week high?
Aclarion Inc trades at $2.34, about 76% below its 52-week high of $9.69 and 16% above the low of $2.02 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of $3.41 is for.
Which stocks are comparable to Aclarion Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aclarion Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $2.34, calculated fair value $3.41 (+46%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACON calculated?
We run Aclarion Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Aclarion Inc currently trades 31 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aclarion Inc (ACON)?
The closing price on Oct 9, 2026 was $2.34. Our model-based fair value is $3.41, about +46% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aclarion Inc right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.25 to $4.26) leaves room in how you read the outcome.
Key figures of Aclarion Inc
How large is the market capitalisation of Aclarion Inc (ACON)?
The market capitalisation of Aclarion Inc is $6.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aclarion Inc (ACON)?
The price-to-sales ratio of Aclarion Inc is 81.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aclarion Inc (ACON)?
Earnings per share at Aclarion Inc are $−6.96. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Aclarion Inc (ACON)?
The return on equity (ROE) of Aclarion Inc is −59.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aclarion Inc (ACON)?
On an EBIT basis the return on assets of Aclarion Inc is −171% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aclarion Inc (ACON)?
The operating margin of Aclarion Inc is −11,503% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aclarion Inc (ACON)?
Revenue at Aclarion Inc is growing +30.5% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aclarion Inc (ACON) generate?
The free cash flow of Aclarion Inc is −$7.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aclarion Inc (ACON) hold?
Aclarion Inc holds more cash than debt, $12.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Aclarion Inc in the live analysis
One click puts Aclarion Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 3, 2026